Moving Foward With Myeloma (MFM)

NCT ID: NCT07236502

Last Updated: 2026-01-12

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 184 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-01-30
• Study Completion Date: 2030-02-28

Brief Summary

The purpose of this project is to evaluate the impact of a 16-week lifestyle program that promotes changes in eating and exercise patterns. The main questions the study will answer are:

Do improvements in eating and exercise patterns lead to improved physical function, quality of life and blood biomarkers of biologial aging among individuals with multiple myeloma? Participants will complete study activities 3-4 times during the study.

1. In-person assessment to measure physical function, height/weight, body composition, and includes a blood draw

2. Surveys completed online or on paper at home

Detailed Description

The study uses a randomized, waitlist control design. Following baseline data collection, participants will be randomized to either the immediate lifestyle intervention group or the waitlist control group. Those who are randomized to the waitlist control group will receive the intervention after the 16-week data collection time point.

Conditions

Multiple Myeloma (MM)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: NONE

Study Groups

Immediate Intervention

16-session intervention that facilitates changes in nutrition and physical activity behaviors to promote improvements in physical function, Patient Reported Outcomes, body composition and general health. The intervention targets plant-based eating, increasing physical activity and strength training.

Group Type: EXPERIMENTAL

Immediate intervention

Intervention Type: BEHAVIORAL

16-session intervention that facilitates changes in nutrition and physical activity behaviors to promote improvements in physical function, Patient Reported Outcomes, body composition and general health

Waitlist control

Participants will be asked to maintain their behavior over the 16 week waitlist period and will receive weekly text message relating positive messages unrelated to lifestyle.

Group Type: ACTIVE_COMPARATOR

Immediate intervention

Intervention Type: BEHAVIORAL

16-session intervention that facilitates changes in nutrition and physical activity behaviors to promote improvements in physical function, Patient Reported Outcomes, body composition and general health

Waitlist

Intervention Type: OTHER

Participants will be asked to maintain their behavior over the 16 week waitlist period and will receive weekly text message relating positive messages unrelated to lifestyle

Interventions

Immediate intervention

16-session intervention that facilitates changes in nutrition and physical activity behaviors to promote improvements in physical function, Patient Reported Outcomes, body composition and general health

Intervention Type: BEHAVIORAL

Waitlist

Participants will be asked to maintain their behavior over the 16 week waitlist period and will receive weekly text message relating positive messages unrelated to lifestyle

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Adult (≥ 18 years)

2. Diagnosed with MM at least one year prior to study enrollment

3. Has access to a cell phone

4. Be deemed "clinically stable" by their physician guided by the following:

1. no near-term changes in planned myeloma-directed therapy anticipated. (e.g., patient who is 3 months from autologous stem cell transplant just starting on maintenance lenalidomide is eligible since maintenance is planned therapy following transplant)

2. no new significant myeloma symptoms (e.g., fractures) meriting changes in anti-neoplastic therapies; AND

3. stable performance status (ECOG 0-2)

5. No reports of severe pain > Grade 3 [defined by the NCI CTCAE as tumor, neurologic, bone, or other pain interfering with self-care ADLs (bathing, dressing, toileting, continence, feeding)].

6. Able to participate in moderate PA and strength training per clinician approval and confirmed by participant

7. Able to understand and willing to sign a written informed consent document

8. English proficient for reading and writing

Exclusion Criteria

1. Individuals with <6 months of life anticipated, coexistent amyloidosis, and/or receiving appetite stimulants will not be approached

2. Fully adherent to the ACS nutrition and physical activity guidelines

3. Currently pregnant or lactating, or anticipating pregnancy

4. On another interventional clinical trial that precludes co-enrollment

5. Psychiatric or other clinical conditions that preclude study compliance

6. Other important medical or safety considerations at the discretion of the investigator(s) and/or approving clinician

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

Loyola University Chicago

OTHER

Sponsor Role: collaborator

Medical College of Wisconsin

OTHER

Sponsor Role: lead

Responsible Party

Melinda Stolley

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Melinda Stolley, PhD

Role: PRINCIPAL_INVESTIGATOR

Medical College of Wisconsin

Locations

Loyola University Chicago

Maywood, Illinois, United States

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Countries

United States

Central Contacts

Melinda Stolley, PhD

Role: CONTACT

mstolley@mcw.edu

(312)735-6044

Facility Contacts

Patricia Sheean, PhD

Role: primary

psheean1@luc.edu

464-220-9216

Melinda Stolley, PhD

Role: primary

mstolley@mcw.edu

414-955-7533

Other Identifiers

1R01CA300310

Identifier Type: NIH

Identifier Source: secondary_id

View Link

PRO00040708

Identifier Type: -

Identifier Source: org_study_id